Roche criticised for refusing access to flu drug data

Clinical study reports – rather than just cherry-picked published research – should be publicly available for all drugs, the reviewers, including Australian evidence-based medicine expert Professor Chris Del Mar, contended in a paper published online in PLoS Medicine.

Clinical study reports were much larger, far more detailed and were used by regulators to determine whether to register a new drug, they said.

When the panel for the Cochrane review of neuraminidase inhibitors read the study reports on Tamiflu, they found significant information had been missing in the published research,